Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
LTC004 in Advanced Sarcoma: NCT06384248 Clinical Landscape Report 2026
16 October 2026
NCT06384248 clinical landscape for Advanced Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
68Ga-NY104 in Metastatic Clear Cell Renal Cell Carcinoma: NCT06389682 Clinical Landscape Report 2026
16 October 2026
NCT06389682 clinical landscape for Metastatic Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Pemigatinib in Dedifferentiated Liposarcoma: NCT06389799 Clinical Landscape Report 2026
16 October 2026
NCT06389799 clinical landscape for Dedifferentiated Liposarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Letrozole in Endometrioid intraepithelial neoplasia: NCT06390904 Clinical Landscape Report 2026
16 October 2026
NCT06390904 clinical landscape for Endometrioid intraepithelial neoplasia: endpoints, sponsor, phase, geography, readouts, asset context and development whit…
9 min read
Sunitinib Malate in Refractory Malignant Solid Neoplasm: NCT06390826 Clinical Landscape Report 2026
16 October 2026
NCT06390826 clinical landscape for Refractory Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
Favezelimab/Pembrolizumab in Mismatch repair-deficient Endometrial Carcinoma: NCT06395090 Clinical Landscape Report 2026
16 October 2026
NCT06395090 clinical landscape for Mismatch repair-deficient Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
Telitacicept in Systemic Lupus Erythematosus: NCT06394063 Clinical Landscape Report 2026
16 October 2026
NCT06394063 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Paclitaxel in Recurrent Ovarian Clear Cell Adenocarcinoma: NCT06393751 Clinical Landscape Report 2026
16 October 2026
NCT06393751 clinical landscape for Recurrent Ovarian Clear Cell Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
ETX-19477 in Metastatic Solid Tumor: NCT06395519 Clinical Landscape Report 2026
16 October 2026
NCT06395519 clinical landscape for Metastatic Solid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
R-5780 in Adenoma: NCT06398418 Clinical Landscape Report 2026
16 October 2026
NCT06398418 clinical landscape for Adenoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ulixertinib in Hematologic Neoplasms: NCT06411821 Clinical Landscape Report 2026
16 October 2026
NCT06411821 clinical landscape for Hematologic Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
A-319 in Systemic Lupus Erythematosus: NCT06400537 Clinical Landscape Report 2026
16 October 2026
NCT06400537 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.